Alexion has routinely featured ... and that was a good call – AstraZeneca has just swooped in with $39 billion cash-and-stock takeover offer. The deal – the largest in the pharma sector ...
Clinical Trials Arena on MSN12d
AstraZeneca’s $1bn hypoparathyroidism drug achieves success at Phase IIIUK-based AstraZeneca’s acquired rare disease drug has met the primary endpoint in a Phase III trial in patients with chronic ...
AstraZeneca’s rare disease firm Alexion is set to expand its genomic medicine portfolio with the acquisition of gene editing specialist LogicBio Therapeutics, in a deal worth approximately $68 ...
Based on the terms of the agreement, BridgeBio will receive a $30 million milestone payment upon approval in Japan, as well ...
LONDON: AstraZeneca Plc’s shares slumped to an eight-month low after it agreed to buy Alexion Pharmaceuticals ... Kingdom pharma giant’s biggest deal ever. The acquisition would push ...
Cooley and Covington & Burling have scored roles in AstraZeneca's $1bn acquisition of Belgian cancer treatment company ...
AstraZeneca has entered the “off-the-shelf” cell therapy space, penning a $1 billion deal to acquire EsoBiotec and its ...
Alexion Pharmaceuticals’ ravulizumab for the prevention of delayed graft function after renal transplantation was granted FDA orphan ...
The FTSE 100 company, which has a market capitalisation of £185.9 billion, confirmed the deal in an announcement to the ...
EsoBiotec SA has entered into a definitive agreement to be acquired by AstraZeneca ( NASDAQ: AZN) for up to $1 billion, on a ...
AstraZeneca added eneboparatide to the Alexion and AstraZeneca rare disease pipeline through the acquisition of Amolyt Pharma in July 2024, in a deal valued around $1.05bn. Shareholders received ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback